You are here

Resistance ‘compromising’ fight against malaria

Published: 
Wednesday, April 11, 2012

 

Scientists have found new evidence that resistance to the front-line treatments for malaria is increasing. They have confirmed that resistant strains of the malaria parasite on the border between Thailand and Burma, 500 miles away from previous sites. Researchers say that the rise of resistance means the effort to eliminate malaria is “seriously compromised.” The details have been published in The Lancet medical journal. For many years now the most effective drugs against malaria have been derived from the Chinese plant, Artemisia annua. It is also known as sweet wormwood. In 2009 researchers found that the most deadly species of malaria parasites, spread by mosquitoes, were becoming more resistant to these drugs in parts of western Cambodia.
 
This new data confirms that these Plasmodium falciparum parasites that are infecting patients more than 500 miles away on the border between Thailand and Burma are growing steadily more resistant. The researchers from the Shoklo Malaria Research Unit measured the time it took the artemisinin drugs to clear parasites from the bloodstreams of more than 3,000 patients. Over the nine years between 2001 and 2010, they found that drugs became less effective and the number of patients showing resistance rose to 20 per cent. Prof Francois Nosten, who is part of the research team that has carried out the latest work, says the development is very serious. “It would certainly compromise the idea of eliminating malaria that’s for sure and will probably translate into a resurgence of malaria in many places,” he said.
 
Untreatable malaria
Another scientist involved with the study is Dr Standwell Nkhoma from the Texas Biomedical Research Institute. “Spread of drug-resistant malaria parasites within South East Asia and overspill into sub-Saharan Africa, where most malaria deaths occur, would be a public health disaster resulting in millions of deaths.” Artemisia annua plant The drug artemisinin is derived from the Artemisia annua plant. The scientists cannot tell if the resistance has moved because mosquitoes carrying the resistant parasites have moved to the Burmese border or if it has arisen spontaneously among the population there. Either way the researchers involved say it raises the spectre of untreatable malaria.
 
“Either the resistance has moved and it will continue to move and will eventually reach Africa. Or if it has emerged, now that artemisinin is the standard therapy worldwide then it means it could emerge anywhere,” Prof Nosten told the BBC.“If we were to lose artemisinin then we don’t have any new drugs in the pipeline to replace them. We could be going back 15 years to where cases were very difficult to treat because of the lack of an efficacious drug.” Artemisinin is rarely used on its own, usually being combined with older drugs to help fight the rise of resistance. These artemisinin based combination therapies are now recommended by the World Health Organisation as the first-line treatment and have contributed substantially to the recent decline in malaria cases in many regions. Prof Nosten says the current spread of resistance could be similar to what happened in the 1970s with chloroquine, a drug that was once a front-line treatment against the disease.  (BBC)

Disclaimer

User comments posted on this website are the sole views and opinions of the comment writer and are not representative of Guardian Media Limited or its staff. Guardian Media Limited accepts no liability and will not be held accountable for user comments.

Please help us keep out site clean from inappropriate comments by using the flag option.

Guardian Media Limited reserves the right to remove, to edit or to censor any comments. Any content which is considered unsuitable, unlawful or offensive, includes personal details, advertises or promotes products, services or websites or repeats previous comments will be removed.

Before posting, please refer to the Community Standards, Terms and conditions and Privacy Policy